South Korea’s SK Biopharmaceuticals to raise more than $850m in country’s second largest IPO since 2017

SK Biopharmaceuticals’ more than $850 million IPO will be South Korea’s largest since 2017

South Koreas SK Biopharmaceuticals to raise more than 850m in countrys second largest IPO since 2017                                 

South Korean drug company SK Biopharmaceuticals is to raise more than $850 million (£658m, €771m) through a planned initial public offering (IPO) in January in what is said to be the country’s biggest listing in two years.

SK Biopharmaceuticals has chosen Citigroup and NH Investment & Securities as lead managers for the deal, which is the largest IPO since mobile gaming company Netmarble raised $2.3 billion in May 2017.

A preliminary application for the IPO was submitted to the Korea Exchange by the company late last month.

The listing comes after SK Life Science, the US subsidiary of SK Group, won approval from the US Food and Drug Administration last week for its cenobamate tablets, a drug that treats partial-onset seizures in adults.

The approval of the drug, which will provide clinicians with an “effective medication” for patients, marks the first time a Korean company has independently brought a compound from discovery to US FDA approval.

The approval is based on results from two global, randomised, double-blind, placebo-controlled studies and a large, global, multi-centre, open-label safety study that enrolled adults with uncontrolled partial-onset seizures, taking one to three concomitant anti-epileptic drugs.

The value of IPOs in South Korea has fallen to about $3 billion so far this year, from $6.8 billion in 2017.

FURTHER READING: Pharma companies agree $260m payout over US opioid epidemic

FURTHER READING: Walgreens considering biggest buyout in history

The material provided on this website is for information purposes only and should not be regarded as investment research or investment advice. Any opinion that may be provided on this page is a subjective point of view of the author and does not constitute a recommendation by Currency Com Bel LLC or its partners. We do not make any endorsements or warranty on the accuracy or completeness of the information that is provided on this page. By relying on the information on this page, you acknowledge that you are acting knowingly and independently and that you accept all the risks involved.
iPhone Image
Trade the world’s top tokenised stocks, indices, commodities and currencies with the help of crypto or fiat
iMac Image
Trade the world’s top tokenised stocks, indices, commodities and currencies with the help of crypto or fiat
iMac Image